Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chevron

Microsoft

Advanced Micro Devices

Bristol-Myers

Comcast

Cisco Systems

Datadog

L3Harris

Southwest Airlines

Newell Brands

ON Semiconductor

Sanofi

Valley National

Vertex Pharmaceuticals

Western Digital

Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook:

Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest

Altria

Value-laden dividend stocks often deliver superior returns compared to other asset classes. AbbVie, a top dividend growth stock, trades at a rock-bottom multiple, despite its above-average yield.

2 No-Brainer Dividend Stocks to Buy This Week

Nexgel

NEXGEL (NASDAQ:NXGL) announced that its CG Converting and Packaging subsidiary has executed a supply agreement with biopharmaceutical giant AbbVie Inc to be a supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.   The provider of high-water-content hydrogel products said by leveraging its proprietary hydrogel technology, the gel pads will be an important component of the body contouring device.

NEXGEL announces supply agreement with AbbVie

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Automatic Data Processing

American Electric Power Company

A. O. Smith

Amphenol

Black Hills

Brown & Brown

Evergy Inc

Gorman-Rupp

Lincoln Electric Hlds

Lockheed Martin

Visa and Exxon Mobil announced dividend increases in October, with Visa increasing its dividend by 15.6% and Exxon Mobil increasing its dividend by 4.4%. Several companies, including AbbVie, American Electric Power, and McDonalds, met or exceeded dividend increase predictions in October. Dividend growth slowed for companies like Amphenol, Black Hills, and Tompkins Financial due to various factors such as the current economic slowdown and flat or lower earnings.

Becton, Dickinson And HP Among 13 Companies Announcing Annual Dividend Increases In The First Half Of November

Archer-Daniels-Midland Company

Emerson Electric

Federal Realty Investment Trust

Hormel Foods

Coca-Cola

Leggett & Platt

National Fuel Gas

Northwest Natural Gas

SJW Group

Stanley Black & Decker

Sysco

Target

Universal Corp

"There is only one criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend payout for a minimum of 50 consecutive years."--Dogs of the Dow. The 49 Dividend Kings screened as of October 25 represented seven of eleven Morningstar Sectors. Broker-targeted top-ten net gains ranged 25.18%-37.56% topped by Target and Gorman-Rupp. By yield, Altria tops all. Top-ten Kingly November yields from ABBV, SWK, FRT, BKH, NWN, CDUAF, MMM, UVV, LEG, & MO averaged 6.12%.

Buy 7 November Dividend Kings, Watch 7 More

AbbVie stock fell today despite easily exceeding estimates for its third quarter. Revenue declines across AbbVie's immunology, oncology, and aesthetics portfolios were partially offset by strong growth from newer neuroscience drugs.

Why AbbVie Stock Fell Today

AbbVie Inc. (NYSE:ABBV ) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President & Chief Operating Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics Tom Hudson - Senior Vice President, R&D & Chief Scientific Officer Scott Reents - Executive Vice President & Chief Financer Roopal Thakkar - SVP, Development & Regulatory Affairs & Chief Medical Officer Conference Call Participants Chris Shibutani - Goldman Sachs Mohit Bansal - Wells Fargo Christopher Schott - JPMorgan Terence Flynn - Morgan Stanley Alice Nettleton - Wolfe Research Vamil Divan - Guggenheim Securities Steve Scala - TD Cowen Gary Nachman - Raymond James Luisa Hector - Berenberg David Risinger - Leerink Partners Geoff Meacham - BofA Securities Evan Seigerman - BMO Capital Markets Operator Good morning and thank you for standing by. Welcome to the AbbVie Third Quarter 2023 Earnings Conference Call.

AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript

AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.

AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View

AbbVie (ABBV) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $3.66 per share a year ago.

AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates

Abbvie (NYSE:ABBV) raised its 2023 profit guidance after a strong quarterly earnings report driven by demand for newer drugs and better-than-expected Humira performance. During 3Q 2023 Abbvie (NYSE:ABBV) posted revenue of $14.2 billion, marking a 7.5% increase from the previous year when it was $13.2 billion and beating the consensus estimate by $0.68 billion.

Abbvie surprises in 3Q with better than expected Humira sales

Shares of AbbVie Inc. NYSE: ABBV have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company's results but has done nothing to change its financial health, position, long-term outlook or ability to deliver value for investors.

High-yield, deep-value AbbVie fell off the patent cliff and lived

AbbVie stock dipped Friday after the drugmaker reported better-than-expected third-quarter metrics, as Humira sales continued to dive.

AbbVie Stock Slips As Humira Struggles Continue, But Drugmaker Raises Outlook

AbbVie raises earnings guidance for fiscal 2023.

AbbVie's Humira Sales Sink 36% but Guidance Lifted on Growth From Other Drugs

AbbVie on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, Humira, and strong demand for newer drugs.

AbbVie raises profit forecast after Humira, newer drugs drive results beat

AbbVie Inc. ABBV, -0.04% on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook, even as its blockbuster autoimmune drug Humira wrestles with new, lower-cost competitors.

AbbVie results beat expectations despite low-cost competition to blockbuster Humira

Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense.

AbbVie Reports Third-Quarter 2023 Financial Results

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for AbbVie (ABBV)

Tandem Diabetes Care

AbbVie has good reasons for investors to take a close look at the stock, even though its best-selling drug recently lost patent exclusivity. Tandem Diabetes Care has plenty of room to increase sales, despite the macroeconomic challenges that have hindered it recently.

Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again

Amgen

Franklin Resources

Helmerich & Payne

Old Republic International

Walgreens

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Best Retirement Stocks to Buy Now

Exxon Mobil

Before U.S. markets open on Thursday, the U.S. Bureau of Economic Analysis will release its first estimate of third-quarter gross domestic product (GDP).

Earnings Previews for AbbVie, Chevron, Exxon Mobil; All Reporting Friday Morning

News for AbbVie Stock (ABBV)